Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of CC-99282 alone and in combination for relapsed or refractory non-Hodgkin lymphoma
MOH_2022-04-12_010738Phase 2Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of golcadomide in non-Hodgkin lymphoma (NHL) (5 arms), sponsored by Celgene Corporation. Started Feb 2022; status: active, not recruiting.
02
Drugs
golcadomide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on MOH_2022-04-12_010738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-04-12_010738.